Article
Pulmonary Aptamer Signatures in Children’s Interstitial and Diffuse Lung Disease
13 Aug 2019
Abstract excerpt
Abstract Rationale Biomarker signatures are needed in children with children’s interstitial and diffuse lung disease (chILD) to improve diagnostic approaches, increase our understanding of disease pathogenesis, monitor disease progression, and develop new treatment strategies. Proteomic technology using SOMAmer (Slow Off-rate Modified Aptamer) nucleic acid–based protein-binding reagents allows for biomarker...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
